Release Date: February 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Is the previous guidance for Stellar Blue's revenue of $120 to $150 million for 2025 still relevant? A: Yes, this guidance is still relevant and is included in the overall guidance. (Respondent: Unidentified_4)
Q: Will Stellar Blue be a separate segment in the new organizational structure? A: Stellar Blue is not a reportable segment. It is managed out of the commercial division with synergies between Gilat's IFC sub-segment and Stellar Blue. The results will be consolidated under the Gilat commercial division. (Respondent: Unidentified_3)
Q: What are the expected costs related to the new organizational structure? A: A presentation on the segment change is available on our website, providing high-level financial results for 2023 and 2024 to assist analysts and investors. (Respondent: Unidentified_3)
Q: Why is there a slight decrease in EBITDA margin in the 2025 guidance compared to 2024? A: Stellar Blue has a lower gross profit, affecting EBITDA. Stellar Blue is in its production ramp-up phase and is expected to be EBITDA positive by the second half of the year. Additionally, significant investments in the defense division, especially in R&D and sales and marketing, contribute to the lower EBITDA ratio for 2025. (Respondent: Unidentified_3)
Q: What is the expected timeline for contracts associated with the Iris Square Consortium? A: Initial discussions are positive. The consortium is expected to issue additional RFIs or RFPs by mid-2025, with awards anticipated before the end of the year and agreements signed in early 2026. However, this timeline may be aggressive, and delays are possible. (Respondent: Unidentified_3)
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。